# US 2010/0303841 A1 · Adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303841 A1
- Document ID: US20100303841A1
- Status: Published application
- Kind: A1
- Application number: 12/745,090
- Filed: 2008-11-27
- Published: 2010-12-02
- Earliest claimed: 2007-11-27
- Inventors: Nira Hochman; Jacob Hochman; Ervin Weiss; Itzhak Ofek
- Web page: https://patentgrep.com/patent/US20100303841A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 36/45: Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
- A61K 39/0011: {Cancer antigens}
- A61K 39/0258: {Escherichia}
- A61K 39/092: {Streptococcus}
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/10: Anthelmintics
- A61P 35/00: Antineoplastic agents
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2740/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The subject invention provides new adjuvant therapy.

## Claims

### Claim 1

An adjuvant comprising NDM (12-30 K) having a molecular weight of from about 12 to about 30 kDa isolated from Vaccinium.

### Claim 2

An adjuvant comprising NDM having a molecular weight of at least about 12 kDa.

### Claim 3 (depends on 1)

A vaccine comprising an adjuvant according to claim 1.

### Claim 4

A use of pharmaceutical composition comprising NDM having a molecular weight of at least about 12 kDa.

### Claim 5

A pharmaceutical composition comprising NDM (12-30 K) having a molecular weight of from about 12 to about 30 kDa.

### Claim 6 (depends on 4)

A pharmaceutical composition according to claim 4 for the treatment of cancer.

### Claim 7 (depends on 6)

A pharmaceutical composition according to claim 6 wherein the cancer is lymphoma.

### Claim 8 (depends on 4)

A pharmaceutical composition according to claim 4 adapted for use in conjunction with a vaccine aimed to prevent an infectious disease.

### Claim 9 (depends on 8)

A pharmaceutical composition according to claim 8 wherein the infectious disease is selected from the group consisting of a bacterial, viral, parasitic, fungal, helminthic and a prion infection.

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9 wherein the infectious disease is a bacterial infection of the respiratory tract.

### Claim 11 (depends on 9)

A pharmaceutical composition according to claim 9 wherein the infectious disease is a bacterial urinary tract infection.

### Claim 12 (depends on 9)

A pharmaceutical composition according to claim 9 wherein the infectious disease is an E. coli associated infection.

### Claim 13 (depends on 12)

A pharmaceutical composition according to claim 12 wherein the E. coli associated infection results in diarrhea and meningitis.

### Claim 14 (depends on 3)

A method of treating and preventing cancer comprising administering a vaccine according to claim 3.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the cancer is lymphoma.

### Claim 16 (depends on 3)

A method of preventing an infectious disease comprising administering a vaccine according to claim 3.

### Claim 17 (depends on 16)

A method according to claim 16 wherein the infectious disease is selected from the group consisting of a bacterial, viral, parasitic, fungal, helminthic and a prion infection.

### Claim 18 (depends on 17)

A method according to claim 17 wherein the infectious disease is a bacterial infection of the respiratory tract.

### Claim 19 (depends on 18)

A method according to claim 18 wherein the infectious disease is a bacterial urinary tract infection.

### Claim 20 (depends on 19)

A method according to claim 19 wherein the infectious disease is an E. coli associated infection.

### Claim 21 (depends on 20)

A method according to claim 20 wherein the E. coli associated infection results in diarrhea and meningitis.

### Claim 22

A fraction of NDM, NDM (12-30 K), having a molecular weight of from about 12 to about 30 kDa isolated from Vaccinium.

### Claim 23 (depends on 22)

A fraction according to claim 22 obtainable by a process comprising (i) ultra filtration of concentrated Vaccinium extract through a membrane excluding 12-30 kD followed by (ii) dialysis at a molecular weight cut-off≧12,000.

### Claim 24 (depends on 22)

A method of preparing a fraction according to claim 22 comprising:
(i) Ultra-filtrating concentrated Vaccinium extract through a membrane excluding 12-30 kD; followed by (ii) dialysing at a molecular weight cut-off≧12,000.

### Claim 25 (depends on 2)

A vaccine comprising an adjuvant according to claim 2.
